Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Sponsor
Zhou Chengzhi
Study ID
NCT05001412
Phase
PHASE1
Status
Unknown

Conditions

  • Extensive Stage Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab; apatinib; carboplatin; etoposide — DRUG
    2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib

Study Details

The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.

Key Dates

Start date
Jan 27, 2021
Status verified
Aug 2021
Primary completion
Jan 25, 2023
Completion
Jan 25, 2024

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort one
    Extensive SCLC patients who are Peripheral type or tumor vascular invasion grade one or less.
  • Experimental: Cohort two
    Extensive SCLC patients who are central type or tumor vascular invasion grade two to three.

Primary Outcome Measure

Safety: Dose-limiting toxicities [ Time Frame: Followed up every 3 weeks. ]

Central Contacts

Related Studies